Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTABARB vs AXOTAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.
Axotal contains butalbital, a barbiturate that enhances GABA-A receptor activity, and acetaminophen, an analgesic and antipyretic whose mechanism is not fully understood but may involve COX inhibition and activation of descending serotonergic pathways.
Sedative,Hypnotic,Anticonvulsant,Preoperative anxiety
Tension headache
15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.
Each tablet: butalbital 50 mg, acetaminophen 300-500 mg, caffeine 40 mg. 1-2 tablets orally every 4 hours as needed, not exceeding 6 tablets per day.
Terminal elimination half-life is 30-60 hours (mean ~40 hours) in adults with normal renal and hepatic function. Longer in elderly or patients with liver disease.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 8-12 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic metabolism via CYP2C9 and CYP2C19; minor pathways involve glucuronidation.
Butalbital is metabolized primarily by CYP2C19; acetaminophen is metabolized mainly via glucuronidation by UGT1A1 and UGT1A6, sulfation by SULT1A1, and minor oxidation by CYP2E1.
Renal excretion of unchanged drug and metabolites. Approximately 70-80% of a dose is eliminated in urine as metabolites (hydroxy and glucuronide conjugates) and <5% as parent drug. Minimal biliary/fecal elimination (<5%).
Renal excretion of unchanged drug (60-70%) and glucuronide conjugates (10-20%); biliary excretion (5-10%); fecal elimination (<10%).
Approximately 20-25% bound to plasma proteins (albumin).
98-99% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.5-0.6 L/kg in adults. Higher Vd suggests distribution into total body water and tissues; may increase in obesity.
0.15-0.25 L/kg, indicating distribution mainly in extracellular fluid and limited tissue penetration.
Oral: 95-100% (well absorbed). Rectal: 80-90%. IM: 80-100%.
Oral: 85-95%; intramuscular: 90-100%; intravenous: 100%.
e GFR 30-50 m L/min: reduce dose by 25%. e GFR <30 m L/min: avoid use or use 50% reduction with caution.
No specific guidelines; contraindicated in severe renal impairment (Cr Cl <30 m L/min). Use with caution in mild-moderate impairment due to acetaminophen and butalbital accumulation.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). In Child-Pugh A or B, reduce dose or extend interval; maximum acetaminophen 2000 mg/day, avoid butalbital if possible.
0.5-1 mg/kg/dose orally every 6-8 hours; maximum 30 mg/dose. Not recommended for children under 6 years.
Not recommended for children under 12 years. For ages 12-18: same as adult dose (1-2 tablets) but limit to 4 tablets per day and monitor for sedation.
Initiate at 7.5-15 mg orally 2-3 times daily; increase slowly. Avoid in frail elderly. Monitor for paradoxical excitation.
Start at lower dose (1 tablet every 6 hours) due to increased sensitivity to butalbital (c NS depression, falls) and acetaminophen hepatotoxicity risk; limit to 4 tablets per day, avoid in frail elderly.
May be habit forming; potential for abuse and dependence. Abrupt discontinuation may precipitate life-threatening withdrawal symptoms.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Hepatotoxicity is usually associated with doses exceeding 4000 mg per day and often involves more than one acetaminophen-containing product.
Respiratory depression, especially when combined with other CNS depressants; tolerance and dependence; withdrawal seizures; use with caution in hepatic impairment and elderly.
Hepatotoxicity with acetaminophen overdose; risk of rhabdomyolysis, angioedema, Stevens-Johnson syndrome; butalbital dependence and withdrawal; CNS depression; impairment of mental or physical abilities; avoid concurrent alcohol use.
Hypersensitivity to barbiturates, porphyria, severe respiratory insufficiency, history of substance abuse.
Hypersensitivity to barbiturates or acetaminophen; porphyria; severe hepatic impairment; respiratory depression; history of substance abuse.
Avoid grapefruit juice as it may inhibit metabolism and increase sedative effects. Take with food if gastrointestinal upset occurs. Limit caffeine intake as it may reduce sedative efficacy.
Avoid alcohol intake; concurrent use increases risk of acetaminophen hepatotoxicity. Grapefruit juice may increase caffeine levels; limit consumption. High-fat meals may delay absorption of butalbital. Maintain adequate hydration; caffeine has mild diuretic effect.
Butabarbital is a barbiturate classified as FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly oral clefts, neural tube defects, and cardiovascular anomalies. Second and third trimesters: Potential for fetal dependence, withdrawal syndrome, and impaired brain development. Chronic use may cause fetal growth restriction and preterm birth.
Pregnancy Category D. First trimester: Risk of cardiovascular malformations (e.g., Ebstein anomaly), neural tube defects, and oral clefts increased with lithium exposure. Second and third trimesters: Increased risk of fetal/neonatal toxicity including cardiac arrhythmias, hypoglycemia, polyhydramnios, preterm birth, and neonatal goiter. Avoid if possible; weigh risks vs. benefits.
Barbiturates are excreted into breast milk in low concentrations. M/P ratio is approximately 0.5-0.6. Chronic high-dose use may lead to infant sedation and difficulty feeding. Monitor infant for signs of drowsiness, lethargy, or poor suckling. Use caution, especially in neonates or preterm infants.
Lithium is excreted into human milk (M/P ratio 0.3-0.8). Breastfeeding is not recommended due to risk of neonatal toxicity (hypotonia, hypothermia, cyanosis, ECG changes). Monitor infant serum levels if breastfeeding is continued.
Pregnancy induces hepatic microsomal enzymes, increasing barbiturate metabolism. Higher doses (increased by 30-50%) may be required to maintain therapeutic levels. Monitor serum drug levels if needed, especially in third trimester. Postpartum, reduce dose to prepregnancy levels to avoid toxicity.
Dose adjustments are often necessary due to increased glomerular filtration rate and expanded plasma volume. Monitor serum levels closely (every 2-4 weeks in second and third trimesters). Dose may need to be increased or given in divided doses (e.g., 3 times daily) due to faster clearance. Postpartum: reduce dose promptly to pre-pregnancy levels within 24 hours after delivery to avoid toxicity from narrowed volume of distribution.
Butabarbital is a short-acting barbiturate with a rapid onset; monitor for respiratory depression, especially when combined with other CNS depressants. Use with caution in hepatic impairment due to prolonged half-life. Tolerance and dependence develop with prolonged use; abrupt discontinuation may precipitate withdrawal seizures. Barbiturates induce CYP450 enzymes, potentially reducing efficacy of oral contraceptives, warfarin, and corticosteroids.
AXOTAL (butalbital/acetaminophen/caffeine) is a combination analgesic for tension-type headaches. Butalbital is a barbiturate with addiction potential; limit use to less than 2 days per week to avoid medication overuse headache (MOH). Acetaminophen hepatic toxicity risk increases with chronic alcohol use or pre-existing liver disease. Caffeine may cause withdrawal headaches upon abrupt cessation.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may cause severe sedation or respiratory depression.,Do not drive or operate heavy machinery until you know how this medication affects you.,Do not stop taking abruptly; withdrawal can cause anxiety, tremors, and seizures. Taper under medical supervision.,This medication may be habit-forming; store in a safe place to prevent misuse.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Inform your doctor of all medications you take, including herbal supplements and over-the-counter drugs.
Do not exceed 4 tablets per day to avoid acetaminophen overdose (max 4000 mg/day).,Avoid alcohol while taking this medication due to risk of liver damage.,This drug can be habit-forming; use only as prescribed for headache attacks, not for prophylaxis.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Discontinue and seek medical help if you experience signs of liver injury (jaundice, dark urine) or allergic reaction (rash, swelling).,Caffeine content may interfere with sleep or exacerbate anxiety; limit other caffeine sources.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTABARB vs AXOTAL, answered by our medical review team.
BUTABARB is a Barbiturate that works by Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.. AXOTAL is a Barbiturate Combination Analgesic that works by Axotal contains butalbital, a barbiturate that enhances GABA-A receptor activity, and acetaminophen, an analgesic and antipyretic whose mechanism is not fully understood but may involve COX inhibition and activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTABARB and AXOTAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTABARB is: 15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.. The standard adult dose of AXOTAL is: Each tablet: butalbital 50 mg, acetaminophen 300-500 mg, caffeine 40 mg. 1-2 tablets orally every 4 hours as needed, not exceeding 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTABARB and AXOTAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTABARB is classified as Category C. Butabarbital is a barbiturate classified as FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly oral clefts, neural tube defects, an. AXOTAL is classified as Category C. Pregnancy Category D. First trimester: Risk of cardiovascular malformations (e.g., Ebstein anomaly), neural tube defects, and oral clefts increased with lithium exposure. Second an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.